MedTrace Logo

The Development of a Human Model of Respiratory Syncytial Virus Infection

NCT01349543 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The aim of this study is to understand the immune response (how the body fights infection) to Respiratory Syncytial Virus (RSV). This virus usually causes a simple 'common cold' illness in healthy adults, but can cause wheezing and lung problems in young infants and the elderly. The investigators want to understand why this is, in order to develop vaccines and treatments.

Participants will include 30-40 healthy adults age 18-55 years. Study procedures will include brief medical exams, breathing tests, a diary of symptoms, blood tests, samples of fluid (lavage) and cells from the nose, throat and lungs. All participants will receive the virus via drops in the nose. The duration of the study for all subjects will be 6 weeks.

Conditions

  • Respiratory Syncytial Virus Infections
  • Respiratory Viral Infections

Interventions

BIOLOGICAL

RSV A Memphis 37

Intranasal administration

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Peter Openshaw · Imperial College London

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-10-31
Completion
2014-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01349543 on ClinicalTrials.gov